140 related articles for article (PubMed ID: 28144804)
1. A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas.
Hayama T; Miura K; Uchiike A; Nakagawa M; Tsutsumi D; Sakagami M; Yoshida Y; Takei M
Int J Clin Pharm; 2017 Apr; 39(2):380-385. PubMed ID: 28144804
[TBL] [Abstract][Full Text] [Related]
2. The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital.
Jung JW; Kang HR; Lee SH; Cho SH
Oncology; 2014; 86(3):127-34. PubMed ID: 24480856
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma.
Hong J; Kim JY; Ahn HK; Lee SM; Sym SJ; Park J; Cho EK; Ahn JY; Park S; Lee SP; Shin DB; Lee JH
Support Care Cancer; 2013 Apr; 21(4):1145-52. PubMed ID: 23111943
[TBL] [Abstract][Full Text] [Related]
4. A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma.
Tsutsumi D; Hayama T; Miura K; Uchiike A; Tsuboi S; Otsuka S; Hatta Y; Kishikawa Y
Int J Clin Pharm; 2022 Apr; 44(2):366-373. PubMed ID: 34894347
[TBL] [Abstract][Full Text] [Related]
5. Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma.
Ohata S; Takenaka K; Sugiyama D; Sugimoto T
Adv Hematol; 2022; 2022():3688727. PubMed ID: 35189630
[TBL] [Abstract][Full Text] [Related]
6. Use of Patient and Disease Characteristics as Predictive Indicators of Rituximab Infusion-Related Reactions in Adult Malignant Hematology Patients at an Academic Medical Center.
Kowalski KE; Adams CB; Voils SA; Wheeler SE
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):723-728. PubMed ID: 31530473
[TBL] [Abstract][Full Text] [Related]
7. A novel prednisone premedication protocol significantly decreases infusion‑related reactions of rituximab in newly diagnosed diffuse large B‑cell lymphoma.
Ding J; Leng Z; Gu H; Jing X
Oncol Lett; 2023 Jun; 25(6):258. PubMed ID: 37205922
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
9. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.
Davis TA; Maloney DG; Grillo-López AJ; White CA; Williams ME; Weiner GJ; Dowden S; Levy R
Clin Cancer Res; 2000 Jul; 6(7):2644-52. PubMed ID: 10914705
[TBL] [Abstract][Full Text] [Related]
10. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
[TBL] [Abstract][Full Text] [Related]
11. Intralesional anti-CD20 antibody for low-grade primary cutaneous B-cell lymphoma: Adverse reactions correlate with favorable clinical outcome.
Eberle FC; Holstein J; Scheu A; Fend F; Yazdi AS
J Dtsch Dermatol Ges; 2017 Mar; 15(3):319-323. PubMed ID: 28177583
[TBL] [Abstract][Full Text] [Related]
12. Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study.
Pritchard CH; Greenwald MW; Kremer JM; Gaylis NB; Rigby W; Zlotnick S; Chung C; Jaber B; Reiss W;
BMC Musculoskelet Disord; 2014 May; 15():177. PubMed ID: 24884454
[TBL] [Abstract][Full Text] [Related]
13. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
[TBL] [Abstract][Full Text] [Related]
14. Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar.
Courville J; Nastoupil L; Kaila N; Kelton J; Zhang J; Alcasid A; Nava-Parada P
BioDrugs; 2021 Jul; 35(4):459-468. PubMed ID: 34152584
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting.
Muntañola A; Arguiñano-Pérez JM; Dávila J; de Villambrosia SG; Carpio C; Jiménez-Ubieto A; Salar A;
Clin Transl Sci; 2023 Feb; 16(2):305-312. PubMed ID: 36385738
[TBL] [Abstract][Full Text] [Related]
16. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for developing infusion reaction after rituximab administration in patients with B-cell non-Hodgkin's lymphoma.
Tachi T; Yasuda M; Usui K; Umeda M; Nagaya K; Osawa T; Ichihashi A; Noguchi Y; Goto H; Kasahara S; Takahashi T; Goto C; Teramachi H
Pharmazie; 2015 Oct; 70(10):674-7. PubMed ID: 26601425
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and predictors of infusion-related reactions to rituximab in patients with B-cell non-Hodgkin lymphoma.
Faqeer N; Alrabie R; Al-Haddadin R; Ma'koseh M
J Chemother; 2023 Oct; ():1-8. PubMed ID: 37860948
[TBL] [Abstract][Full Text] [Related]
19. Infusion-related reactions to rituximab: frequency, mechanisms and predictors.
Paul F; Cartron G
Expert Rev Clin Immunol; 2019 Apr; 15(4):383-389. PubMed ID: 30580638
[TBL] [Abstract][Full Text] [Related]
20. Sixty-minute infusion rituximab protocol allows for safe and efficient workflow.
Dotson E; Crawford B; Phillips G; Jones J
Support Care Cancer; 2016 Mar; 24(3):1125-9. PubMed ID: 26268782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
